Asia stocks drift lower with Fed in focus; Australia falls with RBA hold on tap
Investing.com - H.C. Wainwright has reiterated its Buy rating and $12.00 price target on Altimmune (NASDAQ:ALT), currently trading at $3.87, ahead of upcoming 48-week data from the company’s Phase 2b IMPACT trial. According to InvestingPro data, analysts maintain a strong Buy consensus with price targets ranging from $1 to $28.
The firm’s decision comes after Roche announced on September 18 that it would acquire 89bio for up to approximately $3.5 billion, primarily for its lead MASH compound pegozafermin, which is currently in Phase 3 development.
In discussions with H.C. Wainwright, Altimmune management emphasized that recent business development validates both hepatic and metabolic mechanisms as complementary approaches, suggesting there is room for multiple successful treatments in the market.
Investors are focused on the upcoming 48-week readout from Altimmune’s IMPACT trial and an End-of-Phase 2 meeting, with data expected in a November-December window. The company is designing a potential pivotal Phase 3 program to succeed on both biopsy and non-invasive test frameworks.
Near-term priorities for Altimmune include demonstrating durable improvements across various liver health measurements, including iron-corrected T1, enhanced liver fibrosis, and vibration-controlled transient elastography liver stiffness measurement, while maintaining strong weight loss results and tolerability.
In other recent news, Altimmune Inc. reported its second-quarter 2025 financial results, surpassing expectations with an earnings per share of -$0.27, compared to the forecasted -$0.31. This positive earnings surprise was accompanied by promising trial results for its NASH treatment. Additionally, Altimmune has appointed Linda M. Richardson as Chief Commercial Officer. Richardson brings over 30 years of experience in sales, marketing, and business development, having previously held a similar position at Intercept Pharmaceuticals. Her appointment follows Intercept’s acquisition by Alfasigma. These developments mark significant changes for Altimmune as it continues to advance its clinical-stage biopharmaceutical endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.